Therapeutic potential of RNA interference in drug-resistant cancers

被引：22

作者：

Lage, Hermann ^{[1
]}

机构：

[1] Charite Campus Mitte, Inst Pathol, D-10117 Berlin, Germany

来源：

FUTURE ONCOLOGY | 2009年 / 5卷 / 02期

关键词：

cancer; gene therapy; RNAi; RNA interference; shRNA; siRNA; MEDIATED MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN INHIBITOR; MDR1; GENE-EXPRESSION; TUMOR-CELL GROWTH; ACUTE MYELOID-LEUKEMIA; DOUBLE-STRANDED-RNA; IN-VIVO REVERSAL; HAIRPIN RNA; JET-INJECTION; DOWN-REGULATION;

D O I：

10.2217/14796694.5.2.169

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Resistance including multidrug resistance to chemotherapy is a common clinical problem in patients suffering from cancer. Multidrug resistance is often mediated by overexpression of transmembrane xenobiotic transport molecules belonging to the superfamily of ATP-binding cassette (ABC)-transporters. Inhibition of ABC-transporters by low-molecular weight compounds in cancer patients has been extensively investigated in clinical trials, but the results have been disappointing. Thus, alternative experimental therapeutic strategies for overcoming multidrug resistance are under investigation. These include the application of RNA interference (RNAi) technology. Various RNA! strategies were applied to reverse multidrug resistance in different tumor models in vitro and in vivo, Results and conclusions of these RNAi studies as well as their potential impact for the development of potential RNA! therapeutics will be discussed.

引用

页码：169 / 185

页数：17

共 151 条

[1] The small GTPase R-Ras regulates organization of actin and drives membrane protrusions through the activity of PLCε [J].

Ada-Nguema, AS ;

Xenias, H ;

Sheetz, MP ;

Keely, PJ .

JOURNAL OF CELL SCIENCE, 2006, 119 (07) :1307-1319

[2] Validating survivin as a cancer therapeutic target [J].

Altieri, DC .

NATURE REVIEWS CANCER, 2003, 3 (01) :46-54

[3]

Arora S, 2004, MOL PHARMACOL, V66, P460

[4] Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression [J].

Bargou, RC ;

Jurchott, K ;

Wagener, C ;

Bergmann, S ;

Metzner, S ;

Bommert, K ;

Mapara, MY ;

Winzer, KJ ;

Dietel, M ;

Dorken, B ;

Royer, HD .

NATURE MEDICINE, 1997, 3 (04) :447-450

[5]

BIEDLER JL, 1970, CANCER RES, V30, P1174

[6] 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets [J].

Birmingham, A ;

Anderson, EM ;

Reynolds, A ;

Ilsley-Tyree, D ;

Leake, D ;

Fedorov, Y ;

Baskerville, S ;

Maksimova, E ;

Robinson, K ;

Karpilow, J ;

Marshall, WS ;

Khvorova, A .

NATURE METHODS, 2006, 3 (03) :199-204

[7] Stable suppression of tumorigenicity by virus-mediated RNA interference [J].

Brummelkamp, TR ;

Bernards, R ;

Agami, R .

CANCER CELL, 2002, 2 (03) :243-247

[8] The role of 2′-5′ oligoadenylate-activated ribonuclease L in apoptosis [J].

Castelli, JC ;

Hassel, BA ;

Maran, A ;

Paranjape, J ;

Hewitt, JA ;

Li, XL ;

Hsu, YT ;

Silverman, RH ;

Youle, RJ .

CELL DEATH AND DIFFERENTIATION, 1998, 5 (04) :313-320

[9] Stable suppression of MDR1 gene expression and function by RNAi in Caco-2 cells [J].

Celius, T ;

Garberg, P ;

Lundgren, B .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 324 (01) :365-371

[10] Effect of blocking VEGF, hTERT and Bcl-xl by multiple shRNA expression vectors on the human laryngeal squamous carcinoma xenograft in nude mice [J].

Chen, Shi-Ming ;

Wang, Yan ;

Xiao, Bo-Kui ;

Tao, Ze-Zhang .

CANCER BIOLOGY & THERAPY, 2008, 7 (05) :734-739

← 1 2 3 4 5 6 7 8 9 10 →